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DOI 10.1016/j.cmet.2012.02.003We read with great interest the paper by
Matsubara and collaborators defining a
new function for progranulin as an adipo-
kine potentiating high-fat diet-mediated
insulin resistance through IL-6 (Matsu-
bara et al., 2012). We would like to draw
the attention of the reader to the potential
relevance of these findings for the neuro-
degenerative diseases fronto-temporal
dementia (FTD) and amyotrophic lateral
sclerosis (ALS).
FTD, the most common cause of
dementia in the elderly after Alzheimer’s
disease, is characterized by the degener-
ation of neurons in the frontal and tem-
poral lobes of the brain leading to a range
of behavioral symptoms. FTD co-occurs
with ALS in multiple families, sometimes
in the same patient, and both diseases
share common genetic causes and similar
pathological lesions, suggesting that
they represent two extremes of a clinical
spectrum. Null mutations in the progranu-
lin gene are the most frequent cause of
familial FTD (Cruts et al., 2006), and pro-
granulin genetic variation is also amodifier
of age of onset and disease duration in
ALS (Sleegers et al., 2008). Matsubara’s
findings may therefore have implications
for our understanding of FTD and ALS.
First, loss of progranulin in progranulin
mutant FTD patients could cause aperipheral energymetabolism phenotype.
Indeed, decreased peripheral levels of
progranulin are observed in progranulin
mutant FTD patients (Schofield et al.,
2010). Matsubara and collaborators
report that progranulin knockout mice
are resistant to high-fat diet (HFD) and
display decreased IL-6 levels, thereby
increasing insulin sensitivity upon HFD.
Whether loss of progranulin leads to
similar consequences in FTD patients
harboring a progranulin mutation is un-
known, and to our knowledge no study
has focused on adipose tissue in FTD
patients. Interestingly, abnormal eating
behavior, including overeating and prefer-
ence for sweet food, is a typical symptom
of the behavioral variant of FTD and is
associated with hypothalamic degenera-
tion (Piguet et al., 2011). Contrasting
with the results of Matsubara, proganulin
mutant FTD patients displayed increased
circulating IL-6 levels (Bossu` et al.,
2011), but confounding dietary and/or
endocrine factors were not studied.
Hence, Matsubara’s findings call for a
complete metabolic phenotyping of FTD
patients. Importantly, such studies were
performed in ALS and led to the conclu-
sion that peripheral energy deficit precip-
itates neurodegeneration in this disease.
This paved the way for several clinicaltrials targeting nutrition in this disease
(Dupuis et al., 2011). In all, the potential
dysregulation of energy homeostasis in
progranulin-mediated FTD as well as its
contribution to the neurodegeneration
warrants further investigation.
Matsubara’s findings also have potential
consequences for the design of
therapeutic strategies in FTD. A very
straightforward therapeutic strategy for
FTD would be to stimulate the expression
of progranulin from the nonmutant allele.
Recent studies identifiedseveral candidate
drugs, including inhibitors of the v-ATPase,
as possible inducers of progranulin secre-
tion (Capell et al., 2011). In the brain, such
increasedprogranulin releasewouldbeex-
pected to yield neuroprotection (Van
Damme et al., 2008); Matsubara’s findings
suggest, however, that a potential side
effect of such a treatment could be the
development of insulin resistance. This
should be taken into account in the design
of potential clinical trials in FTD.
In summary, the results of Matsubara
and colleagues are of direct interest not
only for increasing the understanding of
the pathomechanisms of insulin resis-
tance as explicitly stated by the authors,
but also for the two diseases currently
genetically associated with progranulin,
namely FTD and ALS.15, March 7, 2012 ª2012 Elsevier Inc. 269
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DOI 10.1016/j.cmet.2012.02.007The points raised by Dupuis, Petersen,
and Weydt (Dupuis et al., 2012)
regarding our findings (Matsubara et al.,
2012) are intriguing. We found that
PGRN-deficient mice exhibit decreased
body weight, increased insulin sensitivity,
and decreased respiratory quotient
compared to wild-type mice only when
they are exposed to high-fat diet (HFD);
there are no differences in these meta-
bolic parameters between wild-type
mice and PGRN-deficient mice under
normal chow conditions. This suggests
that ablation of PGRN suppresses HFD-
induced obesity by consuming lipids
more preferentially than carbohydrates.
It will be interesting to study the effects
of dietary factors, e.g., HFD, on energy
metabolism and insulin sensitivity in
fronto-temporal dementia (FTD) in a clin-
ical setting.
Dupuis, Petersen, and Weydt mention
that inducers of PGRN secretion, which
are candidate drugs to yield neuropro-
tection, might cause insulin resistance.
Our data also suggest a related process:inhibitors of PGRN secretion and/or
antagonists of PGRN used to protect
against insulin resistance and obesity
might impair the neuroprotective effect
of PGRN. In these cases, tissue-specific
PGRN inducers or blockers might be
considered, according to disease state.
Apart from loss-of-function mutations
in FTD, increased levels of PGRN expres-
sion in the brain have been reported in
amyotrophic lateral sclerosis, Alzheimer’s
disease, and Creutzfeldt-Jakob disease
(Cruts and Van Broeckhoven, 2008).
Accumulating evidence indicates that
insulin resistance and type 2 diabetes are
associated with the pathogenesis and
pathophysiology of neurodegenerative
diseases in humans (Luchsinger and Gus-
tafson, 2009). In addition, a recent paper
has shown that impairment of insulin
signaling in brain induces hyperphosphor-
ylation of Tau, a hallmark of neurodegen-
erative diseases (Kim and Feldman,
2012). Since PGRN directly inhibits insulin
signaling in adipocytes, high levels of
PGRN in brain might impair insulinsignaling in neuronal cells and contribute
to the pathogenesis and pathophysiology
of certain neurodegenerative diseases.
We agree that identification of PGRN
as a causative factor for impaired insulin
signaling opens the way to investigations
of the mechanisms linking insulin re-
sistance, type 2 diabetes, and neuro-
degenerative diseases as well as the
mechanisms of HFD-induced obesity.REFERENCES
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